In this issue:
Zenocutuzumab in NRG1 fusion-positive cancers
Primary tumour SBRT, mediastinal chemo-RT and adjuvant immunotherapy for locally advanced NSCLC
5-year survival in advanced NSCLC with PD-L1 ≥50% treated with first-line pembrolizumab
Bodyweight gain with alectinib for ALK+ NSCLC
Datopotamab deruxtecan vs. docetaxel for advanced/metastatic NSCLC
Pemetrexed and platinum ± pembrolizumab for EGFR-mutated, metastatic nonsquamous NSCLC
Osimertinib ± ramucirumab in EGFR-mutated metastatic NSCLC
Durvalumab ± tremelimumab + chemotherapy in first-line metastatic NSCLC
Nivolumab + ipilimumab-based treatment in metastatic NSCLC and tumour PD-L1 <1%: long-term survival
Sunvozertinib for EGFR-TKI-resistant NSCLC with EGFR mutations
Please login below to download this issue (PDF)